What Telix Pharmaceuticals Ltd's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 3 |
| Sells | 0 | 0 |
| Total trades | 1 | 4 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 4 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Smith Darren Charlton | Group Chief Financial Officer | Sep 07 | Open-market buy · P | +2,071 | $9.66 | +$20K | 13,992 |
| Behrenbruch Christian | MD & Group CEO | Apr 29 | Open-market buy · P | +33,435 | $14.87 | +$497K | 20,742,935 |
| Behrenbruch Christian | MD & Group CEO | Apr 28 | Open-market buy · P | +34,500 | $14.48 | +$500K | 20,709,500 |
| Smith Darren Charlton | Group Chief Financial Officer | Mar 29 | Exercise / conversion · M | +1,111 | — | — | 11,921 |
Loading...
